DUBLIN – Shareholders in Galapagos NV enjoyed an 18 percent stock uptick Wednesday as filgotinib, the company's blockbuster-in-waiting, aced the first of three phase III trials in rheumatoid arthritis (RA) and whetted appetites for further phase III read-outs over the next nine months. Its partner, Gilead Sciences Inc., of Foster City, Calif., also traded up, by about 3 percent. That represents a combined valuation increase of about $3.5 billion across the two companies.